Different Therapeutic Approaches for Dry and Wet AMD

Area of Science:

• Ophthalmology
• Retinal Diseases
• Vision Science

Background:

• Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in older adults.
• AMD presents in two forms: dry AMD (more common, characterized by waste accumulation) and wet AMD (less common, involving abnormal blood vessel growth).
• Current understanding of AMD etiology is incomplete, though risk factors like age, smoking, and genetics are identified.

Purpose of the Study:

• To review current evidence on treatments for both dry and wet age-related macular degeneration.
• To provide particular attention to therapeutic strategies for dry AMD, for which no treatments currently exist.
• To summarize the efficacy of VEGF inhibitors in managing wet AMD and discuss ongoing research for both forms.

Main Methods:

• Literature review of current evidence regarding AMD treatments.
• Analysis of therapeutic approaches for dry and wet AMD.
• Examination of the role of VEGF inhibitors in wet AMD management.

Main Results:

• No treatments are currently available for dry AMD; however, lifestyle modifications and supplements may reduce risk or slow progression.
• VEGF inhibitors are the primary treatment for wet AMD, effectively halting new blood vessel growth and potentially improving vision if diagnosed early.
• VEGF inhibitors cannot reverse existing damage, highlighting the need for further research.

Conclusions:

• Effective treatments for dry AMD remain an unmet need, with current research focusing on novel therapeutic avenues.
• Early diagnosis and timely treatment with VEGF inhibitors are crucial for managing wet AMD and preserving vision.
• Lifestyle factors play a significant role in AMD risk and progression, underscoring the importance of preventative measures.